Alpha Cognition Inc. Common Stock (ACOG) 是一家上市公司 屬於 金融服務 板塊，經營於 Financial - Conglomerates 產業. 公司總部位於 Vancouver, BC, 加拿大. 現任CEO為 Michael E. McFadden.
ACOG 擁有 IPO日期為 2024-11-12, 5 名全職員工, 在 NASDAQ Global Market, 市值為 $104.84M.
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
